Company news articles found here detail internal and external events that may be interesting for all stakeholders. Whether it’s CSR activities, product launches, collaborations or reports on events, you can stay up-to-date on the latest Sysmex news.
2023/03/13 | PRODUCT
Sysmex Life Science expands its product portfolio with the SENTiFIT® 800 Analyser – a totally automated and high throughput analyser for faecal immunochemical testing
Sentinel Diagnostics, an Italian company focused for more than 40 years on the development and production of in vitro diagnostics for the most advanced clinical chemistry, immunochemistry, molecular diagnostics and chromatography platforms, announced the launch of the SENTiFIT® 800 Analyser, a fully automated and high throughput system for faecal immunochemical test (FIT). Through Sysmex, the SENTiFIT® 800 Analyser will be distributed throughout EMEA as part of the FIT offering.
2023/03/08 | CORPORATE
Sysmex and Siemens Healthineers Establish Global Agreement to Supply Hemostasis Instruments and Reagents as OEMs
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO, Hisashi Ietsugu) announced that, on February 28, 2023, it signed a global OEM agreement on hemostasis products with Siemens Healthcare Diagnostics Inc. (HQ: NY, U.S.A.) (“Siemens Healthineers”) under which each company will supply the other with their products in the diagnostic field of hemostasis on an OEM basis.
2023/03/02 | CORPORATE
From Neumünster to the world: Reagents from Sysmex
Medical professionals in doctors' practices and hospitals take blood or urine samples every day and send them to laboratories for analysis. Especially for blood samples, it is highly likely that they are analysed with a Sysmex analyser. At the Neumünster site, the company Sysmex Europe SE produces the necessary reagents and distributes them worldwide. They are used, among other things, in the analysis of blood and urine samples in the Sysmex analysers.
2023/02/07 | CORPORATE
Notice of Changes in Representative Directors
Sysmex Corporation announces that it has resolved to change the representative directors as stated below.
2022/12/22 | PRODUCT
Sysmex Receives Manufacturing and Marketing Approval for an Assay Kit to Identify Amyloid Beta (Aβ) Accumulation in the Brain, a Cause of Alzheimer's Disease, Using a Small Amount of Blood
Measurement of Plasma Aβ Using Automated Immunoassay System HISCL™-5000/HISCL™-800
2022/11/30 | CORPORATE
Sysmex opens its subsidiary in Saudi Arabia
Sysmex, a company specialising in healthcare technology and a world leader in haematology diagnostics and services, celebrated the evening of the opening ceremony of its subsidiary in the Kingdom of Saudi Arabia on 29 November 2022.
2022/11/03 | PRODUCT
OGT launches SureSeq™ Myeloid Plus panel and Universal NGS Complete Workflow
Launch of several new solutions to support OGT’s growing NGS portfolio
2022/10/03 | CORPORATE
Sysmex and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy
Aiming for the Research & Development and Early Commercialization of Regenerative Medicine Products Using Stem Cells, etc.
2022/09/27 | PRODUCT
Sysmex Launches the UF-1500 Fully Automated Urine Particle Analyzer, a New Product for the Urine Sediment Testing Field
Product Lineup Expanding for Small and Medium-sized Facilities
2022/08/24 | CORPORATE
OGT significantly expands global reach
Expansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes
2022/08/01 | CORPORATE
Pilot, Inc. Becomes Wholly-owned Sysmex Subsidiary Through the Acquisition of Outstanding Shares
Reinforcing Software Design and Development Capabilities
2022/07/01 | PRODUCT
Sysmex Launches Sample Transportation System Modules for XR™-Series of Automated Hematology Analyzer
The world’s first automated quality control material measurements contribute to greater automation and efficiency in clinical testing
2022/07/01 | PRODUCT
Sysmex Europe has launched the XQ-520 fully automated haematology analyser
Out now: Sysmex XQ-520 3PD haematology analyser
2022/06/27 | PRODUCT
Completion of Declaration of Conformity to the European IVD Directive for an Assay Kit that Measures Plasma Amyloid Beta (Aβ) Using the Automated Immunoassay System HISCL™-5000/HISCL™-800
Testing Method that Assists in the Identification of Aβ Accumulation in the Brain
2022/06/10 | CORPORATE
Bayerische Hausbau and MATRIX lay the foundation stone for the new work campus FLOW in Hamburg
The new work campus FLOW in Hamburg is becoming a reality: The MATRIX Group and Bayerische Hausbau laid the foundation stone today together with anchor tenant Sysmex Europe and the Second Mayor Katharina Fegebank.
2022/05/27 | CORPORATE
The Ajinomoto Foundation, Sysmex, and NEC initiate a cross-industry co-creation project to improve maternal and child health and nutrition in the Republic of Ghana
Contributing to Universal “Nutrition” Health Coverage
2022/05/25 | PRODUCT
Sysmex Europe SE and Sysmex Inostics GmbH launch two CE-IVD certified Plasma-SeqSensei™ liquid biopsy kits: Solid Cancer IVD Kit and Breast Cancer IVD Kit
Sysmex Inostics, a global leader in blood-based circulating tumour DNA (ctDNA) analysis, together with Sysmex Europe SE, announce the introduction of two IVD-certified Plasma-SeqSensei™ (PSS) kits to the EMEA region.
2022/05/02 | CORPORATE
Astrego Diagnostics AB Becomes Wholly-owned Sysmex Subsidiary through the Acquisition of Outstanding Shares
Commercialization of Rapid Antimicrobial Susceptibility Test to Reinforce Structure for Promoting AMR Countermeasures
2022/04/28 | CORPORATE
Sysmex Employee to Receive “Medal with Purple Ribbon” in Spring 2022 Medal of Honor Awards
Sysmex Corporation employee Toshihiro Mizukami has been selected to receive the Medal with Purple Ribbon, one of the medals of honor to be bestowed in spring 2022.
2022/04/22 | CORPORATE
Sysmex Europe ranks among Germany’s Top 100 employers by Great Place To Work®
Sysmex Europe is proud to announce that Sysmex Europe SE is listed in the top 100 best workplaces by Great Place To Work® Deutschland again this year. It is ranked 17th in the ‘501-2000 employees’ category.
2022/04/11 | PRODUCT
Sysmex Europe has launched its new three-part differential automated haematology analyser XQ-320, adding excellence in quality to this important market segment
Sysmex Europe has recently launched its new three-part differential system ‘XQ-320 XQ-Series Automated Haematology Analyser’, answering to the needs of this important high-volume market segment.
2022/04/11 | PRODUCT
Sysmex Europe launches CE-IVD-marked Flow Cytometer XF-1600, offering clinical flow cytometry laboratories robust and reliable immunophenotyping
Sysmex Europe, a trusted provider of automated workflow solutions in the disciplines of haematology, urinalysis and haemostasis, announces the launch of its Flow Cytometer XF-1600 which has received CE marking, indicating its compliance with the European IVD Regulation and IVD use.
2022/03/01 | CORPORATE
Sysmex Europe will exhibit at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine in Munich, Germany, 11–13 April 2022
Sysmex Europe will be present at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, which will take place in Munich, Germany, from 10 to 14 April 2022.
2022/02/15 | CORPORATE
Sysmex Establishes Subsidiary in Saudi Arabia
Reinforcing Sales, Service, and Support Structures to Expand Business in a Growing Market
2022/01/18 | CORPORATE
Sysmex R&D Center Europe and “academist” begin collaborating in providing academic research funds in Europe
“academist” and Sysmex R&D Center Europe collaborate in exploring and granting academic research in Europe in the healthcare area at the European universities’ research labs. Scientific researchers can apply for the research funds through academist’s website.
2022/01/05 | PRODUCT
Sysmex Files for Manufacturing and Marketing Approval for an Assay Kit that Assists in Identification of Amyloid Beta (Aβ) Accumulation in the Brain
Measurement of Plasma Aβ Using Automated Immunoassay System HISCL-5000/HISCL-800
2021/12/08 | CORPORATE
Discover the fighter in you – through our latest antimicrobial resistance (AMR) awareness campaign!
The 2021 #AMRfighter campaign to raise awareness of antimicrobial resistance shows us that making small changes can make a big difference to help mitigate the growing problem.
2021/10/20 | PRODUCT
Sysmex Europe and Inpeco launch the next gamechanger in urinalysis
Read more about the first and only bi-directional system that transports racks between the Sysmex UN-Series urinalysis analysers and Inpeco's TLA system.
2021/10/15 | CORPORATE
Sysmex Europe wins awards in the programme ‘Excellence in learning 2021’ by Brandon Hall Group
Following the success in 2019, Sysmex Europe receives two bronze awards for ‘Best customer training program’ and ‘Best advance in creating a learning strategy’ by the Brandon Hall Group this year.
2021/10/04 | PRODUCT
Sysmex Launches Caresphere™ XQC, an External Quality Assessment App
Enhancing the Reliability of Testing Results and Efficiency of Laboratory Operations with the Expansion of Caresphere
2021/09/30 | CORPORATE
Sysmex Europe plans new working environments in the new headquarters in Hamburg
The Sysmex Group, international manufacturer and provider of innovative analytical instruments and services for laboratory diagnostics, is on a continuous course of growth and innovation. To accommodate this development, Sysmex Europe will relocate its headquarters for the EMEA region (Europe, Middle East and Africa) from Norderstedt to Hamburg.
2021/09/14 | PRODUCT
Sysmex launches its Sample Preparation System PS-10 in EMEA – a new product to make clinical flow cytometry testing more efficient
Sysmex Europe GmbH announces the launch of the automated flow cytometry sample preparation system PS-10 in the EMEA region.
2021/07/13 | PRODUCT
Sysmex launches new products for the haemostasis field in the EMEA region: automated blood coagulation analysers CN-3500 and CN-6500 using chemiluminescence enzyme immunoassay (CLEIA) technology to enhance the testing workflow
Sysmex Europe GmbH launches new haemostasis analysers CN-3500 and CN-6500 that can run chemiluminescence enzyme immunoassays to enhance the testing workflow.
2021/07/12 | PRODUCT
Sysmex and Inpeco announce the connection of the CN-3000/CN-6000 haemostasis analysers to the FlexLab™ Laboratory Automation System
Sysmex is expanding its haemostasis solution portfolio and is collaborating with Inpeco once again. Three Sysmex haemostasis analysers – starting with CS-5100, and now CN-3000 and CN-6000 – are connectable to Inpeco’s FlexLabTM Total Laboratory Automation System.
2021/06/18 | PRODUCT
Sysmex launches HISCL™-5000 and the HISCL™ SARS-CoV-2 Ag Assay Kit in EMEA.
Sysmex Europe GmbH announces the launch of the HISCL™-5000 fully automated random-access immunochemistry analyser and the HISCL™ SARS-CoV-2 Ag Assay Kit in the EMEA region.
2021/06/16 | PRODUCT
Sysmex obtains the first IVDR certification for LYNOAMP™ CK19 E, a Gene Amplification Detection Reagent
Sysmex Europe GmbH announced today that LYNOAMP CK19 E, part of OSNATM method using a molecular biological technique for cancer diagnostics, is the first Sysmex product to be certified by a notified body under the new European In Vitro Diagnostic Medical Devices Regulation (IVDR) on 4 June 2021
2021/06/07 | CORPORATE
Patient stratification and prognostic scores – the value of routine diagnostic parameters in supporting COVID-19 disease management
Identification of COVID-19-positive patients upon hospital admission usually relies on RT-PCR tests, however, clinicians can utilise diagnostic information to make decisions during the first examination of a patient as well. If risk factors are already known, this can be combined with laboratory tests to provide an informed initial evaluation.
2021/04/06 | PRODUCT
Sysmex and Inpeco announce the launch of a new solution that will change the way of urinalysis
Sysmex and Inpeco will collaborate to bring a game-changer to the field of urinalysis. They will combine their experience and expertise to launch an interface solution to the market in Fall 2021.
2021/04/01 | PRODUCT
Sysmex launches Plasma-SeqSensei™ liquid biopsy RUO kits in EMEA
Sysmex Europe GmbH, together with Sysmex Inostics GmbH, announced today that they will launch the Plasma-SeqSensei™ liquid biopsy research use only (RUO) kits for colorectal cancer (CRC), non-small cell lung cancer (NSCLC), melanoma and thyroid cancer.
2021/03/31 | CORPORATE
Sysmex Europe and Sysmex Germany rank among Germany’s Top 100 employers by Great Place to Work®
Sysmex Europe GmbH, together with Sysmex Deutschland GmbH, is officially ranked among Germany’s top 100 employers by Great Place to Work®.
2021/03/08 | CORPORATE
Sysmex Presents Academic Report on Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
Presenting the Most Recent Data at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2021)
2021/02/03 | CORPORATE
Sysmex Corporation Announces Business Results for the First Nine Months of the Fiscal Year Ending March 31, 2021
Sysmex’s announced today the business result of the first nine months of the fiscal year ending March 31, 2021.
2021/02/03 | CORPORATE
Sysmex and Siemens Healthineers Extend Long-standing Global Alliance in Hemostasis Testing
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and Siemens Healthcare Diagnostics Inc. (HQ: NY, U.S.A.; hereinafter, "Siemens Healthineers") today announced that, on February 2, 2021, the two companies agreed to extend their long-standing alliance on global supply, distribution, and sales and service for hemostasis products through at least 2023.
2021/02/03 | CORPORATE
Sysmex establishes new subsidiary in Portugal
Increasing Portuguese Market Presence by Enhancing Sales and After-Sales Support Networks
2021/01/26 | CORPORATE
Sysmex Selected as One of the Global 100's Most Sustainable Companies in the World for the Fourth Time
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today that, it has been selected as one of the 2021 Global 100's Most Sustainable Companies in the World, a ranking conducted by Canadian publisher Corporate Knights.
2021/01/25 | CORPORATE
Sysmex and Roche Renew Agreement for Global Alliance
Transforming a long-standing alliance into one for the next generation
2021/01/14 | CORPORATE
Sysmex Europe GmbH again awarded with certificate for audit berufundfamilie
Sysmex has again received the berufundfamilie certification, recognising family-friendly working conditions and more.
2020/12/23 | PRODUCT
Sysmex Obtains Marketing Approval for the HISCL™ IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in Novel Coronavirus (SARS-CoV-2)-Positive Patients
Target market: Japan
2020/12/18 | CORPORATE
Sysmex Europe GmbH among top 3 employers for IT jobs in MedTech sector
Sysmex Europe GmbH has been named the top 3 German companies for top employers in IT in the MedTech sector. The top picks are surveyed and presented by CHIP and GreatJobs.
2020/12/11 | CORPORATE
Sysmex EMEA’s first virtual congress, Sysmex Expo 2020 – a great success!
From 8-10 December, Sysmex EMEA hosted their first ever virtual congress.
2020/12/04 | CORPORATE
Sysmex America, Inc. attends the global AACC Annual Scientific Meeting & Clinical Lab Expo
Our colleagues on the other side of the globe, Sysmex America, Inc., will be participating in this year’s AACC Annual Scientific Meeting & Clinical Lab Expo. Typically held in a different American city each year, this year’s event will be held virtually.
2020/12/03 | PRODUCT
Sysmex Launches Surgical Robot Unit, hinotori™ Surgical Robot System
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today that it will launch the hinotori Surgical Robot System, a surgical robot unit, and the HF Series Instrument, a reusable active endotherapy device (collectively referred to as "hinotori" hereinafter; manufacturer: Medicaroid Corporation [HQ: Kobe, Japan; President: Kaoru Asano]) on December 4, 2020 for medical institutions in Japan.
2020/11/11 | PRODUCT
Sysmex Obtains Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent
Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800
2020/11/09 | CORPORATE
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood - CTAD
The Content Presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2020/11/05 | CORPORATE
"Conquering the wave" – preparing for the second wave of COVID-19
Sysmex Global Webinar for COVID-19
2020/10/29 | PRODUCT
Sysmex Presents Academic report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
Presenting the Most Recent Data at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2020/10/28 | CORPORATE
Sysmex Europe is one of Germany's best companies for apprentices
For the fourth time, the business magazine CAPITAL, together with the talent platform Ausbildung.de and the personnel marketing experts from TERRITORY EMBRACE, has set out to find Germany's best company for apprentices.
2020/10/26 | PRODUCT
Sysmex Europe GmbH and affiliates now distributors for Genedrive® 96 SARS-CoV-2 Kit
Genedrive® 96 SARS-CoV-2 Kit is a real-time RT-PCR test for the qualitative detection of SARS-CoV-2 nucleic acids. It addresses the need for high-volume throughput testing and is now being distributed by Sysmex Europe.
2020/10/09 | CORPORATE
Sysmex Europe is celebrating 40 years of diagnostic advancement and growth
Sysmex Europe GmbH celebrates 40 years of business in EMEA and looks forward to continuing lighting the way with diagnostics.
2020/09/29 | PRODUCT
Sysmex Applies for Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent
Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800
2020/08/19 | CORPORATE
Updates & information on COVID-19
According to the increasing incidence of COVID-19 worldwide and in particular in EMEA (Europe, Middle East and Africa), we have reviewed our activities and escalated our preventive measures.
2020/08/11 | PRODUCT
Medicaroid receives Japanese regulatory approval for the “hinotori™ Surgical Robot System”, the first made-in-Japan robotic assisted surgery system
Medicaroid Corporation (HQ: Kobe, Japan; President: Kaoru Asano; hereinafter referred to as Medicaroid) announces it received regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the hinotori™ Surgical Robot System.
2020/08/11 | PRODUCT
Collaboration of Medicaroid, Kawasaki Heavy Industries and Sysmex for the business of the“hinotori™ Surgical Robot System”, a robotic assisted surgery system
Medicaroid Corporation (HQ: Kobe; President: Kaoru Asano; hereinafter referred to as Medicaroid) announces the Japanese regulatory approval for the hinotori™ Surgical Robot System.
2020/07/27 | PRODUCT
Sysmex Launches OncoGuide™ NET Expert Panel Support System in Cancer Genome Profiling
- Supporting the Establishment of a System for Efficient Cancer Genomic Medicine -
2020/07/27 | PRODUCT
Sysmex Launches Lab Assay Service for Research on Cytokines Related to the Novel Coronavirus (SARS-CoV-2)
- Aiming to Monitor the Risk of Increasing Severity and Treatment Effects in Clinical Applications-
2020/07/14 | PRODUCT
Sysmex launches next-generation fully automated blood coagulation analysers CN-6000 and CN-3000 in EMEA
Power in a new dimension for the haemostasis laboratory
2020/07/03 | PRODUCT
Sysmex to Launch Novel Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents (for Research)
Using the HISCL™-5000/HISCL™-800 Fully Automated Immunoassay Systems to Realize SARS-CoV-2 Antibody Detection
2020/07/03 | CORPORATE
The City of Kobe, Kobe City Medical Center General Hospital, and Sysmex Corporation Working to Launch from Kobe the Clinical Implementation of a New Test for the Novel Coronavirus
Collaborating with Medical Institutions of the Foundation for Biomedical Research and Innovation at Kobe to Strengthen Measures Allowing Early-Stage Diagnosis and Prediction of Severity
2020/07/03 | CORPORATE
The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluatea SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau
Performance Report onan Antibody Detection Reagent Using Clinical Specimens
2020/07/02 | PRODUCT
Sysmex Obtains First Marketing Approval in Japan for the Automated Hematology Analyzer XN-31 as a Class III Specially Controlled Medical Device to Diagnose Malaria
For Use as a Measure against Imported Infectious Diseases in Japan and Accelerating its Introduction to the Asian and African Markets
2020/06/01 | CORPORATE
Sysmex and OPTiM Jointly Establish New Company to Plan, Develop and Operate Medical AI and IoT Open Platforms and Digital Transformation Solutions
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and OPTiM Corporation (HQ: Minato-ku, Tokyo, Japan; President: Shunji Sugaya) jointly established and began conducting operations at D’PULA Medical Solutions Corporation on June 1, 2020. The company is in charge of planning, developing, and operating solution services that leverage open platforms and applications related to digital medicine.
2020/05/29 | PRODUCT
OSNA label extension for cervical, endometrial and prostate cancer
OSNA (One Step Nucleic Acid Amplification), a molecular diagnostic assay for accurate detection and quantification of lymph node metastases, is now available also for cervical, endometrial and prostate cancer.
2020/05/25 | CORPORATE
Sysmex Donates ¥30 Million to Kobe City Support Fund for Medical Professionals to Support COVID-19 Countermeasures
Our thoughts and prayers are with the families of those who have perished as a result of the novel coronavirus (COVID-19), and we offer our heartfelt sympathy to the patients currently suffering from this disease. We are truly grateful for the efforts of the medical community and all others who are working on the front lines to stop this pandemic from spreading. Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to donate ¥30 million to the Kobe City Support Fund for Medical Professionals to support measures for countering COVID-19.
2020/03/27 | PRODUCT
Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method)
Aiming for early introduction of test kits forin vitrodiagnostic medical devicesin medical institutions
-Japanese market only-
-Japanese market only-
2020/03/05 | CORPORATE
Sysmex Presents Academic Report Related to the Clinical Utility of RAS Gene Mutation Testing for Colorectal Cancer Using Liquid Biopsy
Details of Report on Clinical Utility of OncoBEAM™ RAS CRC Kit presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020)
2020/02/10 | PRODUCT
Magseed® magnetic marker approved for any soft tissue and long-term implantation across Europe
Endomag has received an extended indication for the long-term use of the Magseed® magnetic marker in any soft tissue. The extended indication was approved after the Magseed® marker was found to be accurate and easy to place in the breast and the armpit in a number of clinical studies. CE certification widening follows the 510(k) clearance from the U.S. Food and Drug Administration (FDA), which was received for the same indication already in 2018.
2020/01/29 | CORPORATE
Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has reached an agreement to invest in Astrego Diagnostics AB (HQ: Uppsala, Sweden; CEO: Ove Öhman). Through this investment, Sysmex aims to help commercialize a rapid drug susceptibility test that Astrego is developing for urinary tract infections.
2020/01/14 | PRODUCT
Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland
Hitado GmbH (Hitado), a Sysmex point-of-care subsidiary, and SphingoTec GmbH (sphingotec) have signed an exclusive distribution agreement for the commercialisation of the Nexus IB10 diagnostic platform by Hitado in Germany. Further, Sysmex Suisse AG will commercialise the platform in Switzerland.
2020/01/14 | CORPORATE
Sysmex gives back – supporting social development together
Science and diagnostics are fascinating – at least that’s what we at Sysmex believe. When the opportunity comes along to fuel excitement for science together with other knowledge providers, we take it.
2019/12/20 | PRODUCT
OSNA for lung cancer – the newest addition to our oncology portfolio
OSNA, a molecular assay for accurate detection of lymph node metastases, is now available for lung cancer!
2019/12/02 | CORPORATE
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2019/11/29 | CORPORATE
Sysmex Europe GmbH wins Silver Technology Award from the 2019 Learning In Practice Awards Program by Chief Learning Officer magazine.
Learning awards seem a little bit like in the movie industry – you may get one in one category, but there are always more categories where you can win!
2019/11/07 | CORPORATE
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31
Sysmex’s announced today the financial results of the first six months of the fiscal year ending March 31.
2019/11/05 | CORPORATE
Sysmex Wins Awards in 2019 Kinki Local Commendations for Innovations
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received a Minister of Education, Culture, Sports, Science and Technology Prize, and Encouragement Prizes for Inventions, at the Kinki* Local Commendation for Inventions, sponsored by the Japan Institute of Invention and Innovation.
2019/11/01 | CORPORATE
Sysmex and OPTiM Reach a Basic Agreement on the Establishment of a Joint Venture to Accelerate the Commercialization of Digital Medicine to Support Next-Generation Healthcare and Diagnostics
Aiming toward the Early-Stage Provision of Platforms and Applications Related to Digital Medicine
2019/10/30 | CORPORATE
Industry, Government and Academia Jointly Establish a General Incorporated Association to Promote the Bioresource Business
Jointly Established by Kobe University, the City of Kobe, the Foundation for Biomedical Research and Innovation at Kobe, and Sysmex
2019/10/02 | CORPORATE
Knowledge Is Power - Celebrating 10 Years of Sysmex Academy and More
Medical diagnostics company Sysmex Europe GmbH celebrates the 10th anniversary of the Sysmex Academy in October. Sysmex is the only company to have such a longstanding education system in place for both employees, distributors, and later on, end-customers.
2019/09/19 | PRODUCT
Sysmex Launches Caresphere™ QM, an Operational Support System for Testing Quality Management
Realizing the Operation of High-Quality Clinical Laboratories through our New Caresphere™ Solution
2019/09/17 | CORPORATE
Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Fourth Consecutive Year
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the fourth consecutive year.
2019/09/06 | CORPORATE
Sysmex Europe GmbH wins the Silver Award for ‘Best Customer Training Program’ from the 2019 Brandon Hall Group Excellence in Learning Awards
The nomination was based on the customer learning portal – Sysmex Academy – that would supplement the face-to-face training with a broad selection of digital training media and live webinars.
2019/09/03 | CORPORATE
Japan’s First Automated Hematology Analyzer Registered by the National Museum of Nature and Science as “Essential Historical Material for Science and Technology”
-Using Unique Technology to Cultivate True Automation in Blood Cell Counting-
2019/08/29 | CORPORATE
Hamburg leaders visited Sysmex Corporation in Kobe
At the end of August, a delegation of high-ranking representatives, including Hamburg’s First Mayor Dr Peter Tschentscher, spent one day in Kobe as part of their tour of Japan and China.
2019/07/19 | PRODUCT
Liquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)
Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, the OncoBEAM™ RAS CRC and the Idylla ctKRAS Mutation Test from the BioCartis Group NV.
2019/06/13 | PRODUCT
A welcome addition to our portfolio: Sentinel’s SENTiFOB® analyser with new cap-piercing function, ideal for low-middle throughput, for the detection of faecal occult blood using FOBGold® reagents
To extend its faecal immunochemical testing (FIT) line to cover the low sample throughput segment of faecal occult blood testing (FOBT), Sentinel Diagnostics recently relaunched its SENTiFOB® analyser with a new cap-piercing function. This add-on feature translates into a new and competitive hardware solution in this market segment.
2019/06/04 | PRODUCT
World Anti-Doping Agency Coordinates Global Implementation of Sysmex Analyzers at All Blood Laboratories
Contributing to Clean and Fair Sports Management by Enhancing the Quality of Doping Tests
2019/05/30 | PRODUCT
Sysmex Inostics OncoBEAM™-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations in 183 NSCLC patients in comparison study
Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer Institute (Lyon, France) comparing the performance of Sysmex Inostics BEAMing (beads, emulsion, amplification, and magnetics) assay for EGFR resistance mutations (OncoBEAM-EGFR) to a next-generation sequencing assay (56G Oncology Panel from Swift Biosciences) in non-small cell lung cancer (NSCLC) patients with EGFR sensitizing mutations under first-line tyrosine kinase inhibitor (TKI) therapy.
2019/05/28 | PRODUCT
Sysmex Inostics’ SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM™ enhanced digital PCR technology for detection of mutations in circulating tumor DNA
Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 meeting in Atlanta, Georgia demonstrate how Sysmex Inostics’ novel SafeSEQ ER+/HER2- breast cancer panel can detect clinically relevant mutations in circulating tumor DNA (ctDNA) from patients with metastatic breast cancer with sensitivity equivalent to Sysmex’s highly clinically validated OncoBEAM liquid biopsy testing.
2019/05/13 | CORPORATE
Sysmex Europe GmbH was awarded as ‘Top Employer SME 2019’ and ranked 8th in the category ‘Electronics and Electrical Engineering, Medical Devices’
The award is based on the results of independent data collection carried out by the business magazine FOCUS-Business in cooperation with the employer assessment platform kununu.
2019/05/08 | CORPORATE
Promoting Business Process Restructuring through Digitalization to Reinforce Corporate Foundations and Create New Value
To achieve business process restructuring, we will construct a digital foundation for the corporate management functions that underpin the Group management foundation, as well as for the value chain encompassing research and development, procurement and logistics, manufacturing, and sales and service.
2019/05/08 | CORPORATE
Sysmex Opens Technopark East Site, a Bio-Diagnostic Reagent Base
Strengthening Diagnostic Reagent Functions through an Integrated Structure from the Development of Substances to the Development, Production and Distribution of Bio-Diagnostic Reagents
2019/04/25 | PRODUCT
Sysmex Obtains CE Certification for Automated Hematology Analyzer XN-31, Which Has an Automatic Measurement Function for Red Blood Cells Infected by Malaria Parasites
Contributing to the Early Detection and Treatment of Malaria through Standardized and More Efficient Malaria Testing
2019/03/01 | CORPORATE
Sysmex to Be Special Sponsor of the Kobe Marathon 2019
-We are pleased to have sponsored this exciting event since its inception in 2011-
2018/12/04 | CORPORATE
Sysmex Europe GmbH organises a blood donation and sport event on 3 December
On 3 December, Sysmex Europe GmbH and Sysmex Deutschland GmbH hosted a blood donation and charity event to give back to society. “Be a Hero” was the motto of the event, which showed a large turnout.
2018/12/04 | PRODUCT
With a View to New Value Creation, Sysmex Launches a Research Assay Service for HDL Function Measurement
-Aiming to Prevent Atherosclerosis-Related Diseases and Provide Treatment Opportunities-
2018/12/03 | PRODUCT
Sysmex Launches Revohem FIX Chromogenic, a Blood Coagulation Factor IX Measurement Kit
-Japan’s First Coagulation Factor IX Measurement Kit Using Chromogenic Assay, Helping to Diagnose and Assist in the Treatment of Hemophilia B-
2018/11/28 | CORPORATE
Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization
-To Accelerate Precision Medicine Through Globally Proven Experience-
2018/11/26 | PRODUCT
CALiaGold – The new quantitative immunoassay from Sentinel Diagnostics for calprotectin measurement in SENTiFIT 270 Analyser
Sysmex Europe GmbH and Sentinel Diagnostics will continue their partnership, which now also gives Sysmex Europe the distribution rights for Sentinel's newest FIT line assay: CALiaGold. CALiaGold is a quantitative latex immunoassay for Calprotectin measurement in faeces.
2018/11/05 | PRODUCT
Sysmex Inostics OncoBEAM™ circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers
Recent data published in Annals of Oncology from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution information for response prediction and therapy monitoring for advanced pancreatic cancer patients compared to current established protein biomarkers.
2018/10/26 | CORPORATE
Congratulations to our CEO Hisashi Ietsugu!
Popular management magazine Harvard Business Review (HBR) recently published their 2018 ranking of the world’s top-performing CEOs. Jumping nine places from 2017’s rankings, Hisashi Ietsugu was placed as number nine this year.
2018/10/22 | CORPORATE
Strengthening Our Global R&D Structure to Foster Early-Stage Innovation
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to reinforce its global R&D structure to accelerate R&D that leverages local characteristics.
2018/10/18 | PRODUCT
Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers
Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of clinically-relevant mutations present in circulating tumor DNA (ctDNA) derived from a simple blood draw.
2018/10/02 | CORPORATE
In vitro diagnostics company Sysmex Europe announces executive leadership change
Sysmex Europe GmbH, which oversees Sysmex’s operations in EMEA (Europe, Middle East & Africa), has announced its Chairman and long-time President & CEO Dr Jürgen Schulze decided in early 2018 to retire effective 30 September 2018, however will continue to benefit and support Sysmex as a member and vice-chairman of the MedTech Europe Executive Board.
2018/09/28 | PRODUCT
Sysmex Inostics announces launch of OncoBEAM™ EGFR Kit v2 (RUO) in Europe and Asia
Sysmex Inostics, a subsidiary of Sysmex Corporation and a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, announces the launch of the OncoBEAM™ EGFR Kit v2 for research use only in Europe and Asia. OncoBEAM™ EGFR Kit v2 replaces the EGFR v1 kit and joins Sysmex Inostics’ OncoBEAM™ RAS CRC and BRAF assays which enable laboratories to perform highly sensitive ctDNA analysis of colon and non-small cell lung cancer samples.
2018/08/31 | PRODUCT
Sysmex, Toppan Printing, and RIKEN GENESIS Commence Launch of Fully Automated System (Research Use Only) to Detect Gene Mutations in Cancer Tissue
-Streamlining the Gene Testing Processes to Standardize the Testing-
2018/08/08 | PRODUCT
Sysmex Partec’s CyFlow™ Counter System, a System to Test for CD4+ Lymphocytes, Receives WHO Prequalification
-Aiming to Help Improve the Quality of HIV Diagnosis and Treatment in Emerging Markets and Developing Countries-
2018/08/07 | CORPORATE
Sysmex and JVCKENWOOD Jointly Establish Company to Use Micro and Nano-Fabrication Technology to Develop and Manufacture IVD Biodevices
These in vitro diagnostic (“IVD”) devices will consist of microfluidics to achieve rapid reactions among tiny amounts of specimens and reagents. Creative Nanosystems is expected to commence R&D in October 2018, toward the commercialization of biodevices.
2018/07/10 | CORPORATE
Sysmex Establishes Subsidiary in Egypt and Begins Conducting Direct Sales and Services
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has established a new subsidiary in Egypt and will begin conducting direct sales and services with the aim of expanding its business in the Middle East.
2018/06/27 | CORPORATE
Sysmex, the Foundation for Biomedical Research and Innovation at Kobe, and Kyoto University Begin Joint Research on Technologies for Diagnosing Immunological Diseases
Through joint research, the three organizations aim to create a diagnostic system that will enable the early detection of autoimmune disease and chronic inflammatory disease.
2018/05/14 | PRODUCT
Sysmex Launches New Products in Its System for the Testing of Cancer Lymph Node Metastasis Using the OSNA™ Method: Gene Amplification Detector RD-200 and LYNOAMP™ CK19
-Contributing to Standardization in the Testing of Cancer Lymph Node Metastasis by Shortening Testing Times and Augmenting Processing Capacity-
2018/05/09 | CORPORATE
Sysmex Group Formulates New Long-Term Management Goals
Celebrating Our 50th Anniversary by Taking on New Challenges to Move to the Next Stage
2018/05/09 | CORPORATE
Sysmex Announces “Sysmex Eco-Vision 2025”
—To contribute to a sustainable society—
2018/05/08 | CORPORATE
Sysmex to Establish Bio-Diagnostic Reagent Center
Reinforcing Our Diagnostic Reagent Development and Production Function by Establishing a Location to Handle Integrated Development through Production and Distribution of Bio-Diagnostic Reagents
2018/05/02 | CORPORATE
Sysmex Employee to Receive the “Medal with Purple Ribbon,” a Spring 2018 Medal of Honor
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) employee Junya Inoue has been selected to receive the Medal with Purple Ribbon, medals of honor to be bestowed in spring 2018, for the development of an automated urinalysis analyzer using flow cytometry technology.
2018/04/26 | CORPORATE
Sysmex to Launch JICA Project in the Republic of Ghana: "Collaboration Program for Disseminating Automated Urinalysis Diagnosis Technology”
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) responded to a call by the Japan International Cooperation Agency (JICA) for proposals under the second fiscal 2017 Collaboration Program with the Private Sector for Disseminating Japanese Technology for Social and Economic Development of Developing Countries.
2018/04/09 | CORPORATE
Sysmex Europe GmbH to Transfer Management of All European Installations of The DigniCap Scalp Cooling System Back to Dignitana AB
Dignitana AB, world leader in clinically superior scalp cooling technology, will assume the complete operation from Sysmex Europe GmbH of their DigniLife scalp cooling division.
2018/04/06 | PRODUCT
Sysmex Launches Caresphere™, a New Network Solution
Supporting the Intelligent Use of Information for the Healthcare of the Future, Where the Use of Information is Accelerating
2018/04/03 | PRODUCT
Advanced Medical Care Approval Received for Multiplex Gene Panel Testing to Advancing Personalized Medicine
On April 1, 2018, Multiplex Gene Panel Testing to Advancing Personalized Medicine using the system developed jointly by the National Cancer Center (Location: Tokyo, Japan; President: Hitoshi Nakagama) and Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received approval as Advanced Medical Care. We will begin providing this testing from April 9, 2018.
2018/04/03 | CORPORATE
Sysmex Formulates New Corporate Message:“Lighting the way with diagnostics”
Today, we will begin rolling out this new message globally, throughout the Sysmex Group.
2018/03/21 | CORPORATE
Japan’s first-ever industry-academia alliance to realize the development of innovative medicine in Japan
Implementation of a one-stop bioresource project in Kyoto University, and the establishment of KBBM Co., Ltd. as a model of “industry-in-the-academia” industry-academia partnership
2018/03/18 | PRODUCT
OncoBEAM™ RAS CRC liquid biopsy test now reimbursed in Germany by BARMER
Effective immediately, cancer patients insured by BARMER now have access to Sysmex’s OncoBEAM™ RAS CRC IVD test.
2018/03/09 | CORPORATE
Sysmex to Be Special Sponsor of the Kobe Marathon 2018
-We are pleased to have sponsored this exciting event since its inception in 2011-
2018/02/20 | CORPORATE
Sysmex Celebrates Its 50th Anniversary of Establishment
Gratitude for All the Support over the Past 50 Years and a Commitment to Continue Taking on Challenges toward the Advancement of Healthcare.
2018/02/08 | CORPORATE
Sysmex Middle East in Medlab exhibition 5-8 February 2018 in Dubai- UAE
Sysmex is creating new opportunities, involving more and more stakeholders, and increasingly getting to the root of the core issues our healthcare clients face.
2018/01/22 | PRODUCT
In depth: Performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS liquid biopsy testing for KRAS mutation detection presented at ASCO GI 2018
Sysmex Inostics, a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today highlights results presented at the American Society of Clinical Oncology’s Gastrointestinal Cancer Symposium (ASCO GI) comparing plasma KRAS mutation detection performance between two commercial liquid biopsy testing platforms, OncoBEAM RAS CRC and Idylla ctKRAS Mutation Test.
2018/01/17 | CORPORATE
Liquid Biopsy performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS testing presented at ASCO GI 2018 meeting
Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces data from an abstract of a study comparing the performance of plasma RAS mutation detection performance by two commercial liquid biopsy testing platforms, OncoBEAM RAS CRC and Idylla ctKRAS Mutation Test.